1.
Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R. & Sitarz, R. Gastric
Cancer:
Epidemiology,
Risk
Factors,
Classification,
Genomic
Characteristics and Treatment Strategies. Int J Mol Sci 21(2020).
2.
Group, G. et al. Role of chemotherapy for advanced/recurrent gastric
cancer: an individual-patient-data meta-analysis. Eur J Cancer 49, 1565-77
(2013).
3.
Wang, F., Meng, W., Wang, B. & Qiao, L. Helicobacter pylori-induced gastric
inflammation and gastric cancer. Cancer Lett 345, 196-202 (2014).
4.
Maekita, T. et al. High levels of aberrant DNA methylation in Helicobacter
pylori-infected gastric mucosae and its possible association with gastric
cancer risk. Clin Cancer Res 12, 989-95 (2006).
5.
Maeda, M., Moro, H. & Ushijima, T. Mechanisms for the induction of
gastric cancer by Helicobacter pylori infection: aberrant DNA methylation
pathway. Gastric Cancer 20, 8-15 (2017).
6.
Hinshaw, D.C. & Shevde, L.A. The Tumor Microenvironment Innately
Modulates Cancer Progression. Cancer Res 79, 4557-4566 (2019).
7.
Del Pozo Martin, Y. et al. Mesenchymal Cancer Cell-Stroma Crosstalk
Promotes
Niche
Activation,
Epithelial
Reversion,
and
Metastatic
Colonization. Cell Rep 13, 2456-2469 (2015).
8.
Kuzet, S.E. & Gaggioli, C. Fibroblast activation in cancer: when seed
fertilizes soil. Cell Tissue Res 365, 607-19 (2016).
9.
Chandler, C., Liu, T., Buckanovich, R. & Coffman, L.G. The double edge
sword of fibrosis in cancer. Transl Res 209, 55-67 (2019).
10.
Costa, A. et al. Fibroblast Heterogeneity and Immunosuppressive
Environment in Human Breast Cancer. Cancer Cell 33, 463-479 e10 (2018).
11.
Ishii, G., Ochiai, A. & Neri, S. Phenotypic and functional heterogeneity of
cancer-associated fibroblast within the tumor microenvironment. Adv Drug
Deliv Rev 99, 186-196 (2016).
12.
Unger, C. et al. Stromal-derived IGF2 promotes colon cancer progression
via paracrine and autocrine mechanisms. Oncogene 36, 5341-5355 (2017).
13.
Maeda, M. et al. Cancer cell niche factors secreted from cancer-associated
fibroblast by loss of H3K27me3. Gut (2019).
14.
Goulet,
C.R.
et
al.
Cancer-associated
40
fibroblasts
induce
epithelial-mesenchymal transition of bladder cancer cells through
paracrine IL-6 signalling. BMC Cancer 19, 137 (2019).
15.
Ham, I.H., Lee, D. & Hur, H. Role of Cancer-Associated Fibroblast in
Gastric Cancer Progression and Resistance to Treatments. J Oncol 2019,
6270784 (2019).
16.
Wang, X. et al. Cancer-associated fibroblast-derived Lumican promotes
gastric cancer progression via the integrin beta1-FAK signaling pathway.
Int J Cancer 141, 998-1010 (2017).
17.
Erez,
N.,
Truitt,
M.,
Olson,
P.,
Arron,
S.T.
Hanahan,
D.
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to
Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent
Manner. Cancer Cell 17, 135-47 (2010).
18.
Tao, L., Huang, G., Song, H., Chen, Y. & Chen, L. Cancer associated
fibroblasts: An essential role in the tumor microenvironment. Oncol Lett 14,
2611-2620 (2017).
19.
Pidsley, R. et al. Enduring epigenetic landmarks define the cancer
microenvironment. Genome Res 28, 625-638 (2018).
20.
Du, H. & Che, G. Genetic alterations and epigenetic alterations of
cancer-associated fibroblasts. Oncol Lett 13, 3-12 (2017).
21.
Vizoso, M. et al. Aberrant DNA methylation in non-small cell lung
cancer-associated fibroblasts. Carcinogenesis 36, 1453-63 (2015).
22.
Jiang,
L.
et
al.
Global
hypomethylation
of
genomic
DNA
in
cancer-associated myofibroblasts. Cancer Res 68, 9900-8 (2008).
23.
Lawrence, M.G. et al. Alterations in the methylome of the stromal tumour
microenvironment signal the presence and severity of prostate cancer. Clin
Epigenetics 12, 48 (2020).
24.
Marks, D.L., Olson, R.L. & Fernandez-Zapico, M.E. Epigenetic control of
the tumor microenvironment. Epigenomics 8, 1671-1687 (2016).
25.
Das, P. & Taube, J.H. Regulating Methylation at H3K27: A Trick or Treat
for Cancer Cell Plasticity. Cancers (Basel) 12(2020).
26.
Hnisz, D. et al. Super-enhancers in the control of cell identity and disease.
Cell 155, 934-47 (2013).
27.
Shukla, V., Vaissiere, T. & Herceg, Z. Histone acetylation and chromatin
signature in stem cell identity and cancer. Mutat Res 637, 1-15 (2008).
28.
Snetkova, V. & Skok, J.A. Enhancer talk. Epigenomics 10, 483-498 (2018).
41
29.
Donati, B., Lorenzini, E. & Ciarrocchi, A. BRD4 and Cancer: going beyond
transcriptional regulation. Mol Cancer 17, 164 (2018).
30.
Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature
468, 1067-73 (2010).
31.
De Buck, M. et al. Structure and Expression of Different Serum Amyloid A
(SAA) Variants and their Concentration-Dependent Functions During Host
Insults. Curr Med Chem 23, 1725-55 (2016).
32.
Urieli-Shoval, S., Cohen, P., Eisenberg, S. & Matzner, Y. Widespread
expression of serum amyloid A in histologically normal human tissues.
Predominant localization to the epithelium. J Histochem Cytochem 46,
1377-84 (1998).
33.
Lee, J.Y. et al. Serum Amyloid A Proteins Induce Pathogenic Th17 Cells
and Promote Inflammatory Disease. Cell (2019).
34.
Subbannayya, Y. et al. Identification of differentially expressed serum
proteins in gastric adenocarcinoma. J Proteomics 127, 80-8 (2015).
35.
Yoon, S. et al. NF-kappaB and STAT3 cooperatively induce IL6 in starved
cancer cells. Oncogene 31, 3467-81 (2012).
36.
Miyoshi, H. Gene delivery to hematopoietic stem cells using lentiviral
vectors. Methods Mol Biol 246, 429-38 (2004).
37.
Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W. & Vogelstein, B. A model for
p53-induced apoptosis. Nature 389, 300-5 (1997).
38.
Chan, D.C. et al. Evaluation of serum amyloid A as a biomarker for gastric
cancer. Ann Surg Oncol 14, 84-93 (2007).
39.
Oki, S. et al. ChIP-Atlas: a data-mining suite powered by full integration of
public ChIP-seq data. EMBO Rep 19(2018).
40.
Ignacio, R.M.C. et al. Serum amyloid A predisposes inflammatory tumor
microenvironment in triple negative breast cancer. Oncotarget 10, 511-526
(2019).
41.
Whyte, W.A. et al. Master transcription factors and mediator establish
super-enhancers at key cell identity genes. Cell 153, 307-19 (2013).
42.
Sabari, B.R. et al. Coactivator condensation at super-enhancers links phase
separation and gene control. Science 361(2018).
43.
Zou, Z. et al. Brd4 maintains constitutively active NF-kappaB in cancer
cells by binding to acetylated RelA. Oncogene 33, 2395-404 (2014).
44.
Piha-Paul, S.A. et al. First-in-Human Study of Mivebresib (ABBV-075), an
42
Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in
Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res 25,
6309-6319 (2019).
45.
Uhlar, C.M., Burgess, C.J., Sharp, P.M. & Whitehead, A.S. Evolution of the
serum amyloid A (SAA) protein superfamily. Genomics 19, 228-35 (1994).
46.
Jovanovic, D. et al. Soluble sPD-L1 and Serum Amyloid A1 as Potential
Biomarkers for Lung Cancer. J Med Biochem 38, 332-341 (2019).
47.
Ni, X.C. et al. Serum amyloid A is a novel prognostic biomarker in
hepatocellular carcinoma. Asian Pac J Cancer Prev 15, 10713-8 (2014).
48.
Liu, C., Pan, C., Shen, J., Wang, H. & Yong, L. Identification of serum
amyloid A in the serum of gastric cancer patients by protein expression
profiling. Oncol Lett 3, 1259-1262 (2012).
49.
Choi, H. et al. Augmented Serum Amyloid A1/2 Mediated by TNF-induced
NF-kappaB in Human Serous Ovarian Epithelial Tumors. Immune Netw
17, 121-127 (2017).
50.
Shinriki, S. et al. Aberrant expression of serum amyloid A in head and neck
squamous cell carcinoma. J Oral Pathol Med 39, 41-7 (2010).
51.
Djurec, M. et al. Saa3 is a key mediator of the protumorigenic properties of
cancer-associated fibroblasts in pancreatic tumors. Proc Natl Acad Sci U S
A 115, E1147-E1156 (2018).
52.
Lin, C.Y. et al. Serum amyloid A1 in combination with integrin
alphaVbeta3 increases glioblastoma cells mobility and progression. Mol
Oncol 12, 756-771 (2018).
53.
Chiariotti, L. et al. Epigenetic modifications induced by Helicobacter pylori
infection through a direct microbe-gastric epithelial cells cross-talk. Med
Microbiol Immunol 202, 327-37 (2013).
54.
Yamamoto, K. et al. Stromal remodeling by the BET bromodomain inhibitor
JQ1 suppresses the progression of human pancreatic cancer. Oncotarget 7,
61469-61484 (2016).
55.
Borggrefe, T. & Yue, X. Interactions between subunits of the Mediator
complex with gene-specific transcription factors. Semin Cell Dev Biol 22,
759-68 (2011).
56.
Hajmirza, A. et al. BET Family Protein BRD4: An Emerging Actor in
NFkappaB Signaling in Inflammation and Cancer. Biomedicines 6(2018).
43
Table 1. Primers for RT-qPCR and ChIP-qPCR
Experiment
RT-qPCR
ChIP-qPCR
Region
Primer sequence
Forward
Reverse
SAA1 exon 3-4
TGCCTGGGCTGCAGAAGTGA
TGATCAGCCAGCGAGTCCTC
GAPDH exon 2-3
AGGTGAAGGTCGGAGTCAACG
AGGGGTCATTGATGGCAACA
SAA1 enhancer 1
GCAAAGTGAACGAGCTTCGG
CTCCACCCACTCTCTCAGGA
SAA1 enhancer 2
GACGACAGTCAGGAGCTCAC
CATGTCCCCTCCCATTCCAG
SAA1 promoter
CCAGGCACATCTTGTTCCCT
AGTCCCTGCAGGTCATTTCC
Table 2. Oligonucleotide sequences for shRNA
Region
sh1
sh2
SAA1 exon 3
SAA1 exon 4
Oligonucleotide sequence
Top
Bottom
GATCCAAGCCAATTACATCGGCT
AATTCAAAAAAAGCCAATTACA
CAGACAAACTTCCTGTCAGATT
TCGGCTCAGACAAATCTGACAG
TGTCTGAGCCGATGTAATTGGCT
GAAGTTTGTCTGAGCCGATGTA
TTTTTTG
ATTGGCTTG
GATCCGTGATCAGCGATGCCAG
AATTCAAAAAGTGATCAGCGAT
AGAGAATCTTCCTGTCAGAATT
GCCAGACACAATTCTGACAGGA
CTCTCTGGCATCGCTGATCACTT
AGATTCTCTCTGGCATCGCTGAT
TTTG
CACG
44
Table 3. Deposited Data from ChIP-Atlas
Source
Identifier
ChIP-seq, human fibroblast, H3K4me1
https://www.ncbi.nlm.nih.gov/
GSM2550214
ChIP-seq, human fibroblast, H3K27ac
https://www.ncbi.nlm.nih.gov/
GSM2214081
ChIP-seq, MSC, MED1
https://www.ncbi.nlm.nih.gov/
GSM2802953
ChIP-seq, Detroit 562, RELA
https://www.ncbi.nlm.nih.gov/
GSM2419817
ChIP-seq, MCF 10A, NFB1
https://www.ncbi.nlm.nih.gov/
GSM3184663
ChIP-seq, MCF 10A, STAT3
https://www.ncbi.nlm.nih.gov/
GSM3184665
45
...
論文の公開元へ
